Incorporating ICIs into platinum-doublet regimens improved OS and ORR in ES-SCLC patients with ECOG PS 2 to 3, but not in those with ECOG PS 0 to 1. The study found manageable adverse reactions, with ...

We analyzed deidentified data from an EHR-derived database for patients with advanced non–small cell lung cancer (aNSCLC) at their first line of treatment. Our novel imputation method involved (1) ...

ECOG performance status was found to capture only part of the patient experience in gastric/GEJ adenocarcinoma. Among patients with gastric or gastroesophageal junction (GEJ) adenocarcinoma, those ...

Patient-reported physical function scores are significant predictors of survival and adverse events in multiple myeloma treatment. Physical function has a stronger correlation with patient outcomes ...

Eastern Cooperative Oncology Group performance status (ECOG PS) is a key confounder in comparative effectiveness research, predicting treatment and survival, but is often incomplete in electronic ...